COMPARISON OF GLOBAL REGULATORY GUIDELINES FOR AVAILABILITY OF DIFFERENT BIOWAIVER PROVISIONS AND APPLICATION REQUIREMENTS OF BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) BASED BIOWAIVER.
To waive a complete and systemic Bioequivalence (BE) study, Biowaiver or Request for a Biowaiver is a fast track approach to boost the drug development process. Over the past three-four years the Biowaiver market shows greater number of Biowaiver submissions and the wider use of In-vitro permeability study. Biowaiver is a beneficial approach for getting approval of Abbreviated New Drug Application (ANDA) while, BCS based Biowaiver is the novel approach to gain approval for New Drug Application (NDA) as well as ANDA. A Biopharmaceutics Classification System (BCS) based Biowaiver is an exemption from conducting human bioequivalence studies when active ingredient and dosage form meet criteria of solubility, permeability and dissolution. The Paper covers different kind of Biowaiver approaches and the criteria for the applicability of BCS based Biowaivers in the different geographic scopes with regard to global development strategy. There is a comparison of global guidelines on provisions availability for different types of Biowaiver approaches as well as for requirements of Biowaiver based on BCS. From comparison of different global guidelines it is reviewed that most of the guidance resembles to the USFDA, EU and WHO guidelines because most of the regulatory authorities are following the BCS based Biowaiver concept as one of the three main guidance documents (USFDA, EMA, WHO) or a combination of specific requirements.
2. Nair AK. Statistics on BCS Classification of Generic Drug Products Approved Between 2000 and 2011 in the USA. AAPS Journal. 2012 June; 14: p. 664-6.
3. USFDA [Internet]. FDA; 2000 [cited 2015 Jan 15]. Available from:
4. EMEA [Internet]. EMA; 2010 [cited 2015 Jan 18]. Available from:
5. WHO [Internet]. [cited 2015 Jan 15]. Available from: www.WHO.com
6. hsa.gov [Internet]. HSA. ASEAN; 2004 [cited 2015 Jan 20]. Available from:
7. anvisa.gov.br [Internet]. ANVISA, Brazil;2006 [cited 2015 Jan 25]. Available from:
8. Healthcanada.gc.ca [Internet]. Healthcanada; 2014 [cited 2015 Jan 23]. Available from:
9. CDSCO [Internet]. CDSCO; 2005 [cited 2015 Feb 4]. Available from:
10. MHLW. NIHS. [Internet].Division of Drugs; 2012 [cited 2015 Feb 3]. Available from:
11. Ministry of Health, BPFK [Internet]. National Pharmaceutical control bureau; 2013 [cited 2015 Feb 12]. Available from:
12. FIP, Russia [Internet]. International Pharmaceutical Federation ; 2011 [cited 2015 Jan 25]. Available from:
13. SFDA [Internet]. SFDA; 2012 [cited 2015 Jan 26]. Available from:
14. ICH.org [Internet]. SADC. ICH; 2007 [cited 2015 Jan 26]. Available from:
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM